Core Viewpoint - Jingtai Holdings (02228) experienced a significant stock increase of over 6%, currently trading at 11.4 HKD, following the announcement of a strategic collaboration with Eli Lilly worth up to 345 million USD [1] Group 1: Strategic Collaboration - Jingtai Technology's subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total value potentially reaching 345 million USD, including several million USD in upfront payments and milestone payments [1] - This partnership aims to leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody research platform to enhance internal pipeline research [1] Group 2: Previous Collaborations - This agreement follows a previous collaboration in 2023, where Jingtai Technology and Eli Lilly signed a 250 million USD deal focused on AI small molecule drugs, marking another significant partnership between the two companies [1] Group 3: Ailux's Development - Ailux, established by Jingtai Technology in 2021, has rapidly developed into a major platform for large molecule drug research, achieving significant commercial results in recent years [1] - The platform employs a hybrid research model that combines wet and dry lab approaches, enabling precise AI-driven antibody drug design and engineering, effectively addressing challenges related to high costs and long timelines in drug discovery [1] - Ailux is expected to advance various next-generation antibody drugs designed by AI into later clinical stages, aiming for impactful major commercial collaborations in the future [1]
晶泰控股高开逾6% 就AI赋能双特异性抗体与礼来达成3.45亿美元平台战略合作